Cytoart, Inc
Cytoart is a biotechnology company specializing in anti-idiotype antibodies for CAR-T cell detection, flow cytometry, and clinical monitoring. Our reagents enable highly sensitive and specific detection of CAR-T cells across CD19, BCMA, CD20, GPC3, MSLN, and GD2 targets. We also offer Anti-G4S linker antibodies and copy number detection kits (qPCR).
We provide one of the most comprehensive catalogs covering nearly all FDA-approved CAR-T therapies, with validated sensitivity down to 0.001% (1 in 100,000 cells), and formats compatible with flow cytometry, CyTOF, IHC, and ELISA.
In addition, Cytoart offers custom antibody development and develops VHH nanobody-based solutions for CAR construct design (including CD19, CD20, GPRC5D, and BCMA targets), as well as in vivo CAR-T delivery approaches targeting CD3, CD5, CD7, and CD8.
Our platforms support applications from early research to clinical studies across pharmaceutical R&D, QA/QC, and CRO/ICL workflows.
Products